Jazz Pharmaceuticals plc (JAZZ) Quality Score
Business quality is the primary weakness (avg 35/100). Valuation is the relative bright spot.
Broad-market heuristics · Not a buy/sell signal
Valuation and growth
Valuation
Growth
Under 20x, reasonable relative to earnings
Under 20x cash flow, well covered
5–10% CAGR, steady but not exceptional
5–10% CAGR, steady but not exceptional
Business Quality & Capital Allocation
Heavy dilution above 5%
Expanded 3+pp, strong improvement
Net debt/FCF of 1.7x, somewhat elevated
Below 8%, may not cover cost of capital
Jazz Pharmaceuticals (JAZZ) quality: score, margins and returns
Jazz Pharmaceuticals (JAZZ) scores 64/100 on Intrinsiqq's quality score (a solid business), a weighted blend of 8 metrics each scored 0 to 100, on 19.5% operating margins and 7.4% ROIC. Every metric is computed from SEC filings; this is analysis, not investment advice.
Frequently asked
Is Jazz Pharmaceuticals (JAZZ) a high-quality business?+
Jazz Pharmaceuticals scores 64 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which rates it a solid business on these measures. Recent figures include a 19.5% operating margin and a 7.4% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.
What does Jazz Pharmaceuticals's quality score measure?+
Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from JAZZ's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Jazz Pharmaceuticals scores well and where it falls behind.
What is Jazz Pharmaceuticals's return on invested capital (ROIC)?+
Jazz Pharmaceuticals earns about 7.4% on its invested capital, which is modest. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to JAZZ's margins and growth on this scorecard to judge durability.
How profitable is Jazz Pharmaceuticals?+
Jazz Pharmaceuticals runs an operating margin of about 19.5% and a net margin of about 20.4%. Revenue has grown at roughly 12.5% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from SEC filings, not investment advice.
SourceQuality score computed from the 10-Q filed 27 Jul 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 12 Oct 2026. How this is calculated.
Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.
Related stocks: Pharmaceutical Preparations
Spot a number that looks wrong?
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.